ATHE News and Press, Alterity Therapeutics Limited From 09/26/22

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders PR Newswire - Wearable sensors strongly correlated with clinical scales on motor impa...

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy PR Newswire Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia ...

Alterity Therapeutics ( NASDAQ: ATHE ) said its phase 2 trial of ATH434 to treat patients with Multiple System Atrophy (MSA) was open for enrolment in the U.K. "In a short period of time we have now commenced enrolment in our second region, and we look forward to broad...

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe PR Newswire Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELBOURNE, Australi...

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report PR Newswire Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Pha...

Vancouver, Kelowna, Delta, BC - July 8, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Mining, Biotech, eSport and Plant-Based. Today's stocks have been added to our lists of fr...

Alterity Therapeutics ( NASDAQ: ATHE ) said the first patient was dosed in a a phase 2 trial of ATH434 in Multiple System Atrophy (MSA) MSA is a rare disorder of the nervous system which causes gradual damage to nerve cells in the brain and can affect  breathing, ...

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy PR Newswire MELBOURNE, Australia and SAN FRANCISCO , July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the ...

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23 r d Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOG...

Australian biotech Alterity Therapeutics (NASDAQ:ATHE) announced on Thursday that the authorities in Italy cleared a Phase 2 trial for its lead drug candidate ATH434 in multiple system atrophy (MSA), a rare Parkinsonian disorder. The randomized, double-blind study will be designed to evaluate...